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Abstract
Background: Multiple sclerosis (MS) is an autoimmune disease of 
the central nervous system that affects sensitive and motor functions. 
Many population studies were made with the intent of knowing bet-
ter the most affected groups and the disease manifestations. These 
review analyses some of those studies, evaluating risk factors, es-
pecially genetic relations of Human Leukocyte Antigen DRB1 (HLA-
DRB1) gens, for developing clinical disease.
Method: We have analyzed 57 articles, published between 2009 
and 2014, with the key words “multiple sclerosis”, “genetic associa-
tion studies” and “HLA-DRB1 chains”, through the Scopus database. 
Only 18 articles were eligible for our study; they were read entirely 
and included in the final analysis.
Results: Most studies imply genetic and environmental factors for 
the incidence of MS, its age of starting and prognosis. Previous stu-
dies have shown that many gens are related in MS pathogenesis and 
that interactions between them are important in determining clinical 
manifestations.
Limitations: Different results were observed when different popu-
lations were targeted in the studies.
Conclusion: There is an important relation between HLA-DRB1 
and MS in diverse population groups. Complementary studies are 
needed to know better the importance of environmental factors and 
its interaction with gens in the development of MS. 
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Introduction
Multiple Sclerosis (MS) is a chronic inflammatory 
and degenerative disease of the Central Nervous 
System (CNS) [1, 2]. It presents with a variety of 
pathological process, such as demyelination, axo-
nal injury and inflammation, with auto-reactive T 
cells [3, 4, 2]. The autoimmune response is directed 
against myelin proteins, such as myelin associate 
glycoprotein and myelin oligodendrocyte protein 
[5, 6].
The disease usually begins between 20 and 40 
years of age, though it can occur, less frequently, 
in children and older individuals. Women are 
affected approximately twice as often as men [7, 
6]. Its etiology remains unknown, but the current 
theories points towards an association between 
genetic an environmental factors in MS pathoge-
nesis [8, 2].
Some studies have shown consistent and strong 
genetic relations between Human Leukocyte Anti-
gen (HLA) class II and MS (Ramagopalan et al, 2009 
[9]; Lincoln et al, 2005 [10]) [11]. Some alleles of 
the HLA DRB1 gen have been associated to higher 
the risk of MS, meanwhile, others may be consi-
dered as protective factors for the disease [12, 13, 
11]. The HLA DRB1*15 allele is the most implicated 
for the developing of MS, being well correlated to 
its occurrence [11], and may imply worst prognosis 
[14-16, 11]. HLA DRB1*15 frequently interacts with 
other alleles, which is crucial to influence the course 
of MS [17, 18]. Other alleles associated to greater 
risk of developing MS are HLA DRB1*0405 [1] and 
HLA DRB1*03 [11]. HLA DRB1*11 [17, 22, 11] and 
HLA DRB1*1001 [2] are considered protective alleles 
against MS. 
Furthermore, interactions between alleles or ha-
plotypes of the HLA may occur, modulating the sus-
ceptibility risk of MS, and determining the global 
risk of the disease for each individual genotype [12, 
13, 19, 20, 21]. Due to MS prevalence and clinical 
relevance, it is important to understand its possible 
causes. In this article, we performed a systematic 
review aiming to understand the relation between 
HLA-DRB1 and MS development.
Methods
The present study is a systematic review of literatu-
re, performed at the Scopus database in October 
2014, with the keywords “multiple sclerosis”, “HLA-
DRB1 chains” and “genetic studies association”, in-
cluding articles published between 2009 and 2014. 
Five researchers (TL, LB, SA, GS and JS) conducted, 
independently and blind to each other, a literature 
survey, aiming articles for a possible inclusion. Any 
discrepancies between the five reviewers about the 
analysis of the articles were resolved through con-
sultations with a senior author (MR).
The selection of articles to compose this review 
followed the previously determined eligibility crite-
ria: (1) manuscripts written in English; (2) original 
articles with full text available for online assess at 
Coordination of Improvement of Higher Educational 
Personnel (CAPES) Journal Portal; (3) articles about 
the HLA-DRB1 alleles acting on multiple sclerosis; 
(4) case-control and cohort studies, besides clinical 
trials (Figure 1).
The exclusion criteria adopted was: (1) non-origi-
nal studies, including letters to the editor, reviews, 
and editorials; (2) other designs, such as reviews of 
literature, pilot studies, short communications and 
meta-analysis; (3) Out of the context; (4) full text 
not available at CAPES Journal Portal.
Thereafter, the selected articles through eligibility 
criteria were entirely read by all five authors. The 
extracted data were organized into a matrix, which 
presented authors, sample characteristics, study 
design, journal, category, main findings, limitations 
and conclusion. A few studies approached not only 
the HLA-DRB1 chains as a risk factor for MS but 
also explored the role of other gens increasing MS 
susceptibility.
Later, we compared the selected studies’ findings 
and categorized them in three groups, according to 
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the article subject, aiming to facilitate our analysis: 
(1) Articles about how HLA-DRB1 haplotypes affects 
the multiple sclerosis, (2) Articles about how the 
non-HLA polymorphisms affects the HLA effects on 
MS and (3) Articles about how the HLA-DRB1 alleles 
affects the multiple sclerosis.
We have adopted for this present study ‘Prefe-
rred Reporting Items for Systematic Reviews and 
Meta-Analysis’ (PRISMA) guidelines to reach a 
high pattern of reporting. The PRISMA statement 
consists of a 27-item checklist and a four-phase 
flow diagram, which are used for development of 
systematic reviews and meta-analyses. This state-
ment is useful for ensure a complete and transpa-
rent reporting of the studies that was analyzed. 
Beyond that, the eligibility criteria of this review 
were based in PICO (Patient, Problem, Population; 
Intervention; Comparison, Control, Comparator; 
Outcomes) process.
Results
First of all, the foregoing search strategies resulted 
in 57 studies. After analyzing tittle and abstract of 
all 57 references, 18 articles reached inclusion cri-
teria and were included in the final sample. In this 
regard, all manuscripts were found at the Scopus 
database (Figure 2).
Table 1 summarizes the 18 included studies in final 
sample as well as all data elements that were used 
in the data analysis process. The selected articles 
were later separated in three categories: (1) how the 
HLA polymorphisms affect the multiple sclerosis, (2) 
how the non-HLA polymorphisms affect the HLA 
effects on MS and (3) how the HLA-DRB1 alleles 
affect the multiple sclerosis (Table 1).
Discussion
The influence of hla drb1*1501 allele in ms
In population studies, high MS prevalence areas 
were analyzed, as Lithuania [22]. In that popula-
tion, the HLA DRB1*1501 allele were frequently 
found in patients with progressive MS, being as-
sociated with the beginning of the disease, fe-
male gender and worst prognosis [11-18, 23-26]. 
Smestad et al. (2007) [23], Hensiek et al. (2002) 
[25], Van der Walt et al. (2011) [27], Cree et al. 
(2009) [28] e Wu et al. (2010) [29] have previously 
suggested that this allele may be strongly asso-
ciated to the rising of MS, its first symptoms in 
younger individuals and more aggressive manifes-
tations of the disease [31].
Balnyte et al. (2013) [30] reported that, in more 
than 80% of Lithuanian patients with MS, Oligoclo-
Figure 1:  A chart produced by Scopus databa-
se which represents the total of docu-
ments rated by document type.
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Figure 2: PRISMA 2009 Flow Diagram.
7 of records identified through database searching 0 of additional records identified through other sources
57 of records after duplicates removed
14 of records excluded






















57 of records screened
43 of full text articles assessed for eligibility
18 of studies included in qualitative synthesis 
18 of studies included in qualitative synthesis
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta- Analyses: The PRISMA Statement. PLoS Med 
6(6): e1000097. doi:10.1371/journal.pmed1000097
For more information, visit: www.prisma-statement.org
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Study Design Journal Category Main Findings Limitations Conclusions
Balnyte R, 
Rastenyte D, 












HLA-DRB1 was more found in 
patients with the progressive form 
of the disease. There is a genetic 
association between the HLA-DRB1 
genotype and MS susceptibility. 
People with the progressive form 
of the disease showed that HLA-
DRB1*15 is the most prevalent allelic 
group in this patients, specially the 
younger ones. Further, the HLA-
DRB1 genotype was associated 
with worse prognosis. Besides, 
HLA-DRB1*8 was related to a lower 
degree of disability.
Small sample of MS 
patients. Some clinical 
data was gathered 
retrospectively from the 
medical records. Further 
a large scale studies are 
needed.
There is an association between 
HLA-DRB1 alleles and the 
disease's prognosis. The HLA-
DRB1*15 was related to a lower 
degree of disability. Therefore, 
HLA-DRB1 allelic may have an 








a year of Multiple 
Sclerosis onset.







There are an association among HLA-
DRB1 and EVI5. HLA-DRB1 positive 
groups presents more severe attacks 
by EVI5. EVI5 was associated with an 
unimportant risk of severe attacks. 
That gene was related to a greater 
possibility of worse recovery. Also 
this study evaluated the interaction 
between HLA-DRB1 and CD226A. 
Those associations were related to a 
susceptibility studies.
Analysis was reduced to 
white persons, which 
does that study is not 
able to represent others 
racial groups
There are an association 
among HLA-DRB1 and EVI5. 
HLA-DRB1 positive groups 
presents more severe attacks 
by EVI5. EVI5 was associated 
with an unimportant risk of 
severe attacks. That gene was 
related to a greater possibility 
of worse recovery. Also, this 
study evaluated the interaction 
between HLA-DRB1 and 
CD226A.
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Huang J, 
Yoshi-mura 



















G allele of NOTCH 4 rs422951 was 
negatively associated with only MS, 
but not with non-NMO/NMOSD. This 
allele was also significantly related to 
Multiple Sclerosis as an independent 
resistant allele for this disease in 
Japanese. Moreover, the analysis 
identified two susceptible an three 
resistant haplotypes produced from 
HLA-DRB1*0405, HLA-DRB1*0901 
andrs422951. Besides, G allele was not 
associated with any clinical parameters. 
HLA-DRB1*0405 was positively 
associated with Multiple Sclerosis.
Some genotyping results 
were not validated by 
DNA sequencing. Remains 
unclear if the association 
among NOTCH4 an NMO/
NMOSD and non-NMO/
NMOSD Multiple Sclerosis 
is distinct because the 
sample included both 
MS and NMO patients. 
The NOTCH 4 mutation 
protects against the 
developing Multiple 
Sclerosis.
G allele of NOTCH 4 rs422951was 
negatively associated with only 
MS, but not with non-NMO/
NMOSD. This allele was also 
significantly related to Multiple 
Sclerosis as an independent 
resistant allele for this disease 
in Japanese. Moreover, the 
analysis identified two susceptible 
an three resistant haplotypes 
produced from HLA-DRB1*0405, 
HLA-DRB1*0901 and rs422951. 
Besides, G allele was not 
associated with any clinical 
parameters. HLA-DRB1*0405 



















DQB1 haplotypes were analyzed and 
haplotypes were found to confer 
susceptibility and protection to 
multiple sclerosis
Not disclosed Interactions between HLA-
DRB1-DQB1 haplotypes were 
analyzed and haplotypes were 
found to confer susceptibility 
and protection to multiple 
sclerosis
Yoshimura 
S, Isobe N, 
Yonekawa T, 
et al. [1]
145 patients with 
multiple sclerosis 








Multiple Sclerosis patients without 
DRB1*0405, the frequency of 
DRB1*1501 allele was higher, while the 
DRB1*0901 allele was lower compared 
with healthy patients. Furthermore, 
Multiple Sclerosis patients DRB1*0405 
negative were significantly more likely 
to be positive for antibodies to the 
Epstein-Barr virus nuclear antigen 
compared to healthy patients.
Few number of patients 
enrolled in the study
The DRB1*0405 is related to 
multiple sclerosis in younger age 
and causes a benign course of the 
disease, the detection of this gene 
accounts for the largest number 
of young Japanese Multiple 
Sclerosis patients. Multiple 
Sclerosis patients without this 
gene, has multiple sclerosis and 
similar Western sclerosis.
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The findings indicate that the 
DRB1*1501 allele, the DRB1*1501-
DQB1*0602 haplotype and the 
DRB1*1501/0701- genotype and 
amino acid Leu26 and Phe9 on the 
DQβ1 chain are significantly associated 
with Multiple Sclerosis susceptibility. 
DRB1*1001 was the only allele that 
had a protective effect against Multiple 
Sclerosis. Thus, that the DQB1*0303 
allele was significantly associated with 
disease severity. However, protective 
effect of the DRB1*1001 against 
Multiple Sclerosis and also association 
of DQB1*0303 allele with Multiple 
Sclerosis severity.
Sample size Findings indicate that the 
DRB1*1501 allele, the 
DRB1*1501-DQB1*0602 
haplotype and the 
DRB1*1501/0701- genotype 
and amino acid Leu26 and 
Phe9 on the DQβ1 chain are 
significantly associated with 
Multiple Sclerosis susceptibility. 
DRB1*1001 was the only allele 
that had a protective effect 
against Multiple Sclerosis. Thus, 
that the DQB1*0303 allele 
was significantly associated 
with disease severity. However, 
protective effect of the 
DRB1*1001 against Multiple 
Sclerosis and also association of 

















Haplotype analysis showed that almost 
all DRB1*15 haplotypes were risk 
bearing, and that all A*02 haplotypes 
were protective bearings if they did 
not carry DRB1*15 In addition, was 
found a class I haplotypes, the carrying 
*C-02*05 B*12, which abolished the 
risk of DRB1*15.
Not disclosed Confirmed the role of HLA class 
I and II, in addition to DRB1*15 
and A*02 in susceptibility to 
multiple sclerosis by the inclusion 
of all three HLA genes class I 
classical and their functional 
interaction with DRB1*15 and 
various DRB1 alleles of class I 
genes.
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It was confirmed that *15:01 haplotype 
gives a greater risk of suffering 
from multiple sclerosis. There was 
no association between Vitamin D 
Receptor (VDR) gen variants of Multiple 
Sclerosis, but they modulate moderately 
the risk conferred by *15:01. Sex 
confers a much stronger modulation 
at *15:01-MS, being more remarkable 
in females the risk conferred by 
*15:01. Sex confers a much stronger 
modulation at *15:01-MS, being more 
remarkable in females.
Not disclosed It was confirmed that *15:01 
membership is female specific. 
The HLA-DRB1*15:01 appears to 
be related consistently linked to 








consisting of one 
affected sibling 
and both healthy 
parents (trio), 
and 362 healthy 
siblings (one from 
each family) of 
patients coming 









The test of haplotype DRB1*DQB1* 
confirmed a higher transmission 
rate than expected *13:03-*03:01, 
*04:05-*03:01 and *03:01-*02:01 
haplotypes. In contrast the *16:01-
*05:02 and *15:02-*06:01 haplotypes 
showed a lower than expected rate 
of transmission. The independence of 
the transmission of each haplotype 
was confirmed for all the haplotypes 
associated positively and negatively 
related to *16:01-*05:02 haplotype. The 
study of DRB1 and DQB1, chain protein 
residues showed that the Val / Gly at 
position 86 of the DRB1 chain was the 
only difference between the protector 
*16:01-*15:02 alleles and predisposition 
*15:01 one. As well, the Ala / Val 
residue at position 38 of the DQB1 
chain differentiated positively associated 
*06:02 and the negatively associated 
allele *05:02, *06:01 alleles
Not disclosed The study showed that 
the association of specific, 
independent DRB1*-DQB1* 
haplotypes confer susceptibility 
or resistance to multiple sclerosis 
the population. The data also 
points to the functional role of 
specific residues of DRB1 and 
DQB1 in protein predisposing to 
multiple sclerosis
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hospitals in the 
South of Spain. 
Controls were 
972 blood donors 












It was been found that the tag of 
DRB1*1501, rs3135388 A allele, 
correlated with high expression of 
DRB1, DRB5 and DQB1 genes in a 
Caucasian population. In quantitative 
terms, the MS-risk AA genotype 
carriers of rs3135388 were associated 
with 15.7-, 5.2- and 8.3-fold higher 
expression of DQB1, DRB5 and DRB1, 
respectively, than the non-risk GG 
carriers. The haplotype analysis of 
expression-associated variants in a 
Spanish Multiple Sclerosis cohort 
revealed that high expression of DRB1 
and DQB1 alone did not contribute to 
the disease. However, in Caucasian, 
Asian and African American 
populations, the DRB1*1501 allele was 
always highly expressed.
The nature of the 
HLA, which is highly 
polymorphic.
It is concluded that the DR/DQ 
expression levels, together with 
specific structural properties of 
alleles, seem to be the causual 
effect in multiple sclerosis and in 
other immunopathologies rather 








or living long in 
the northwest 













The results revealed that HLA-
DRB*1501 allele was significantly more 
frequent among patients with Multiple 
Sclerosis compared to the control 
group.
Sample size The results revealed that 
HLA-DRB1*1501 allele was 
significantly more frequent 
among patients with Multiple 










the diagnosis of 













Statistically, the HLA-DRB1*15 allele 
had a much higher frequency in 
patients diagnosed with multiple 
sclerosis when compared with the 
control group.
Not disclosed Statistically, the HLA-DRB1*15 
allele had a much higher 
frequency in patients diagnosed 
with multiple sclerosis when 
compared with the control 
group.
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Was founded 206 OCB-positive 
and 62 OCB-negative patients. The 
HLADRB1*15 allele in OCB-positive 
patients had a higher frequency when 
compared with OCB-negative patients
Not disclosed HLA-DRB1*15 allele is associated 
with OCB-positive patients with 
MS
when studying a Spanish 
Multiple Sclerosis population.
Deschamps 
R, Paturel L, 





patients and 150 
healthy controls. 
All cases and 



















The study confirms that the French 
population has distinct Afro-
Caribbeans susceptibility allele HLA 
involved in Multiple Sclerosis and 
Devic's disease. The first is positively 
associated with HLA-DRB1*15, 
whereas the risk for the latter is 
correlated to HLA-DRB1*03 allele.
Few relatively number of 
NMO patients.
The study confirms that the 
French population has distinct 
Afro-Caribbeans susceptibility 
allele HLA involved in Multiple 
Sclerosis and Devic's disease; 
The first is positively associated 
with HLA-DRB1*15, whereas the 









and 305 healthy 
blood donors 















The results showed that the HLA-
DRB1*15 was positively associated 
with Multiple Sclerosis. The frequency 
of allele HLA-DRB1*11 was reduced 
in the MS patients when compared to 
the control group.
Homozygosis for HLA-
DRB1*15 allele failed to 
show any association 
with Multiple Sclerosis 
susceptibility. 
The HLA-DRB1*15 may be 
considered a risk of susceptibility 
a Multiple Sclerosis. However 
the HLA-DRB1*11 may be 
considered a marker of 
resistance to Multiple Sclerosis in 
Brazilian population.
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MJ, et al. 
[68]

















Several alleles are over represented 
in Multiple Sclerosis patients: 
DRB1*0402, DRB1*1303, DRB1*1501, 
DQA1*0102, DQB1*0302 and 
DQB1*0602. DRB1*0101, DQA1*0101, 
DQB1*0303, and DQB1*0501 showed 
lower frequencies in Multiple Sclerosis 
patients, but only DRB1*0101 and 
DQB1*0303 maintained a negative 
association with the disease.
Not disclosed The results confirm the 
positive association of the 
DR2 haplotype. DRB1*0402-
DQA1*0301-DQB1* showed 
a possible association with 
Multiple Sclerosis. DRB1*0101 
allele may be a possible 




Dinčić E, et 
al. [99]
Subjected group 
consisted of 164 
females and 105 
males, 36,3 ± 
10,5 years age. 
The control group 
consisted of 106 
female and 117 














It was identifying high frequency 
of the tag single nucleotide 
polymorphism (SNP) for HLA-
DRB1β1501, rs3135388, in Multiple 
Sclerosis patients.
Not disclosed The tag single nucleotide 
polymorphism (SNP) for HLA-
DRB1*1501, rs3135388 has 
significant association with MS 



























HLA-DRB1*1501 was significantly more 
frequent among Multiple Sclerosis 
patients. DQA1*0102 haplotype was 
negatively associated with Multiple 
Sclerosis. No significant association was 
found with DQB1*0602 and Multiple 
Sclerosis patients in comparison with 
control group. No significant correlation 
was observed among these alleles with 
sex, type of disease; initial symptoms, 
expanded disability status scale (EDSS), 
as well as age at onset and familial 
multiple sclerosis.
Examining patients 
from different parts of 
the country that may 
have variable ethnic 
backgrounds.
There is no association of above 
HLA haplotypes with clinical 
presentation, disease duration, 
and disability in Iranian patients 
with MS which is in line with 
other previous studies in 
different ethnic groups.
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nal Bands (OCBs) were detected in their cerebrospi-
nal fluid (CSF) [30]. Other studies came to the similar 
conclusions, in Australia (Wu et al., 2011) [29], Turkey 
(Idiman et al., 2009) [31], and Spain (Romero-Pinel 
et al., 2011) [32, 30] OCBs were more frequently 
found in those patients with HLA DRB1*15 allele. 
Balnyte et al. (2013) [30] suggested that this asso-
ciation produces immunological disturbances that 
may affect MS prognosis, with possible regulation 
of other genetic factors may. [30]
The study of Romero-Pinel et al. (2011) [32] 
also demonstrated the association between HLA 
DRB1*15 and OCBs in MS, in the Spanish popula-
tion - as the studies of Kikuchi et al. (2003) [33], 
Wu et al. (2010) [34], Imrel et al. (2006) [35] e Idi-
man et al. (2009) [31,.32] Although, other cohort 
studies have shown that the DRB1*15 predisposes 
MS, regardless the positivity of OCBs in the CSF. 
However, when both factors are positive, the pre-
disposition seems to be more significant [31, 34, 
36, 32].
Back to the Lithuanian population, there is no 
consensus on the role of HLA DRB1*15 in deter-
mining the severity of MS. Kouri et al. (2011) [18] 
concluded that it may be associated with a better 
prognosis18. On the other hand, Van der Walt et 
al. (2011) [27] reported that HLA DRB1*15 have no 
influence on the disease’s severity, except when de-
termining earlier beginning of symptoms. [30].
In Sardinia, where MS also have a high incidence, 
[37, 38] a genomic association study of the Inter-
national Multiple Sclerosis Genetic Consortium, in 
2011 [39], confirmed that DRB1*1501 is the most 
significant genetic factor for developing MS, and its 
interactions with other alleles influences the disease. 
[21].
However, a small number of studies in non-euro-
pean populations, as chinese, iranians, african-ame-
ricans and african-brazilians, have found a lower 
prevalence of DRB1*1501 allele in MS patients (Kelly 
et al., 1995 [40]; Caballero et al., 1999 [41]). [18] Fur-
thermore, Wu et al. (2010) [29] in Western Australia 
reported that the positivity of HLA DRB1*1501 has 
no significant influence in the age of MS beginning. 
[18] 
Romero-Pinel et al. (2011) [11] haven’t found any 
significant association between age of MS develo-
pment and the different HLA alleles in the Spanish 
population. On the contrary, several studies found 
a significant association between a lower age at 
onset and the HLA-DR15 haplotype, the DRB1*15 
allele (Masterman et al., 2000 [42]; Smestad et al., 
2007 [23]; Hensiek et al., 2002 [25]; Cree et al., 
2009 [28]) and other DRB1 alleles (Wu et al., 2010 
[29]). [11].
In addiction, other studies haven’t found any as-
sociation between DRB1*15 allele and the severity 
of the disease (Masterman et al., 2000 [42]; Bar-
cellos et al., 2006 [20]; Hensiek et al., 2002 [25]; 
Weinshenker et al., 1998 [43] and Runmarker et 
al., 1994 [44]).[11] Meanwhile, Vasconcelos et al. 
(2009) [14], Cornu-Rebeix et al. (2008) [15] and Wu 
et al. (2010) [16], in desagreement with the study of 
Silva et al. (Portugal, 2007) [45], have reported that 
patients with positive HLA DRB1*15 were related to 
a worst prognosis, not a better one. [11] 
In Irish patients, positive DR15 were associated 
with earlier beginning of MS and to female gender 
[25, 42, 11] And Irizar et al. (2012) [46], studying the 
Japanese population, concluded that DRB1*15 allele 
confers greater risk of MS only for women [46].
Kollaee et al. (2012) [2] have compared the alle-
les of HLA-DRB1*15 (DRB1*1501, DRB1*1502, 
DRB1*1506, DRB1*1508, DRB1*1511 e DRB1*1515) 
in the Iranian population, and concluded that the 
DRB1*1501 allele is associated with relapsing–remit-
ting multiple sclerosis (RRMS), compared to the con-
trol group. [2] This finding is consistent with some 
other studies conducted in Iranian relapsing–remit-
ting and primary progressive MS patients (Kalanie 
et al., 2000 [47]; Ghabaee et al., 2009 [48]), but it 
is inconsistent with the study conducted by Amir-
zargar et al. (1998) [49], which was performed on 
chronic progressive patients with MS in Iran. [2]
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Although DRB1*1501 was shown to be associa-
ted with MS in many ethnic groups, especially in 
Caucasians (Fernandez et al., 2004) [50], a few stu-
dies in European populations, such as Sardinians, 
and non- European populations, such as Afro Bra-
zilians and Chinese, show that the frequency of the 
HLADR*1501 allele was slightly lower in the patient 
group compared to the controls (Kelly et al., 1995 
[51]; Caballero et al., 1999 [41]; Oksenberg et al., 
2004 [52]) [2].
According to Kankokar et al. (2003) [17], most 
population studies about HLA and MS have focused 
in Europeans, Caucasian Americans, Australians, 
Chinese, Japanese, Jewish and Turkish, in which 
MS predisposition has been frequently associated 
with DRB1*15 and its related alleles (DRB1*1501, 
DQA1*0102, DQB1*0602). [18] Other studies, from 
North Europe, have found a strong relation bet-
ween the haplotype DR15 (DRB1*1501-DQA1*0102-
DQB1*0602) and its alleles and MS. [53, 54].
The majority studies associating alleles and MS 
took place in North Europe [55, 42], but Mediterra-
nean populations [56-58], as north and south Ame-
ricans, have also been the subject of large studies 
[59-61, 11] Australian patients with MS have also 
been strongly associated to the allele [62]. [11]
Other drb1 alleles that affect ms
There are another isolated alleles that can be rela-
ted to MS. For example, HLA DRB1*04 and HLA 
DRB1*01 have been associated to a worst prognosis 
in MS patients [11, 23, 25, 62, 30].
The HLA DRB1*04 allele, further than being re-
lated to rapidly progressive disease [63, 30] –as the 
HLA DRB1*01 allele [11] –, may also be associa-
ted with more Magnetic Resonance Imaging (MRI) 
abnormalities, along with HLA DRB1*09 [63, 30]. 
However, these alleles, especially the DRB1*09, are 
rarely seen and appeared to be no influence on 
clinical signs of MS [64, 30]. 
Balnyte et al. (2013) [30] reported that HLA 
DRB1*01 allele is related with shorter time to reach 
and Kurtze Expanded Disability Status Scale (EDSS) 
of 6, this likely to be related to a worse progno-
sis [30]. Meanwhile, Link et al. (2012) [65] repor-
ted that the HLA DRB1*01 allele has a protective 
effect in MS patients when they are also positive 
for DRB1*15 allele [65]. 
Studies in the Northern Spain populations have 
also demonstrated a protective effect of HLA 
DRB1*01 allele in MS patients, which had a signi-
ficant higher level of positivity compared to control 
groups (Fernández-Morera et al., 2008 [66]; Pina 
et al., 1999 [67]) [68]. In addiction, Brynedal et al. 
(2007) [69] reported that the HLA DRB1*01 may 
be a protective factor alone [68]. DeLuca et al. 
(2007) [70] have also reported that the DRB1*01 
allele segregates with both disease resistance and 
favorable outcome, were founded some sporadic 
MS cases that the DRB1*01 is significantly underre-
presented in malignant compared with benign MS. 
Adding to it, the control groups indicated that the 
DRB1*01 allele seems to diminish the progressive 
disability that characterizes MS in the long term 
and hypothesized that the protective effect of 
DRB1*01 in a replication cohort of affected sibling 
pairs may result from a specific epistatic interaction 
with DRB1*1501. [68].
Yoshimura et al (2012) [1] reported that the HLA 
DRB1*0405 allele may be a significant risk in Japane-
se patients with MS. In their study, the DRB1*0405-
positive subgroup had significant differences com-
pared to the DRB1*0405-negative subgroup, as: 
younger age at disease onset, lower EDSS scores, a 
lower Progression Index (PI), and a lower frequency 
of MS-like brain lesions [1]. As there is an earlier 
age of onset and a lower PI compared with pa-
tients without DRB1*0405, the authors suggested 
that the DRB1*0405-positive subgroup may be the 
only one with a relatively benign disease course and 
a premature age of onset [1].
Also, a tendency of lower positivity of oligoclonal 
IgG bands (OB)/increased IgG index in the CSF has 
been demonstrated, compared to DRB1*0405-ne-
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gative MS patients [1], which agrees with studies in 
Swedish [35] and Japanese [33] populations, which 
have shown that the DRB1*04 is related to OB-
Negative MS patients [1].
On the other hand, in DRB1*0405-negative MS 
Patients a higher frequency of positivity of HLA 
DRB1*1501 has been observed, as of brain lesions 
and increased CSF OB/increased IgG index (Yoshi-
mura et al., 2012) [1].
Yoshimura et al. (2012) [1] have also reported that 
the DRB1*0901 allele has a significant protective 
effect against MS, regardless HLA DRB1*0405 is 
positive or not. This event was demonstrated in a 
meta-analysis performed with Chinese patients, in 
which the DRB1*0901 allele showed its protective 
effects against MS (Qiu et al., 2010). [71] Fujisao et 
al. (1996) [72] reported that the DRB1*0901 allele is 
more frequently found in Asians than in any other 
ethnical group [1], which could reasonably explain 
the lower incidence of MS in Japan and other Asia-
tic countries (Yoshimura et al., 2012). [1].
A Lithuanian study evinced that the HLA DRB1*08 
and *15 alleles were strongly related to the risk of 
MS in the population (Balnytė et al., 2012). [64, 30] 
However, the HLA DRB1*08 allele was more com-
monly found in patients with relapsing-remitting 
MS, which has a lower degree of disability. Fur-
thermore, lower IgG index was documented in the 
patients with the HLA DRB1*08 allele than in those 
without it. [30].
Another gene associated to risk of MS is the 
HLA-DR*17 gen, an allele of DRB1 that, according 
to large study of Dyment et al. (2005) [12] with 
Canadian MS patients, is also associated to higher 
susceptibility of MS [2].
Wu et al. (2010) [29] reported a relation between 
HLA DRB1*0801 allele and an older age of onset 
[30]. And Balnytė et al. (2013) [30] reported that 
this allele is also related to more benign course and 
less severe disability in MS patients [30]. Meanwhile, 
HLA DRB1*13 allele was associated with a younger 
age of onset of MS. [64, 30].
An Iranian study of Kollaee et al. (2012) [2] de-
monstrated that the DRB1*1001 allele was the only 
one with a negative relation with MS, playing a 
protective role against the disease. In addition, 
15 patients in the control group were positive for 
DRB1*1001 allele, meanwhile none of the 120 sick 
patients had it. The authors have also evinced that 
the absence of DRB1*0701 allele, in any genotype 
containing the DRB1*1501 gen, may increase the 
individual risk of MS [2].
Deschamps et al. (2011) [73] discussed about a 
minor protective effect of DRB1*1101 allele in the 
risk of MS, independently of the occurrence of 
DRB1*15 and DQB1*06 alleles. Similar results were 
reported in Malta [58], Italy [56, 74], in Caucasian 
Brazilians (but not in mulattos) [60], Canada [13] and 
in a French Caucasian population [75]. [73].
Kaimen-Maciel et al. (2009) [6] evinced that the 
presence of DRB1*11 allele in MS patients is related 
to resistance in disease development, what shows 
a tendency of a protective role. These authors de-
monstrated that, in homozygosis, the allele may 
confers protection against MS onset [6].
Another studies observed the possible protective 
effect of DRB1*11 allele for MS (Ramagopalan et 
al., 2007 [13]; DeLuca et al., 2007 [70]). [11]. The 
inference results of the high positivity of this allele 
in control groups, meaning it is rather a protective 
factor alone or because of its interactions with other 
alleles implicated in the appearance of MS. [20, 11].
Romero-Pinel et al. (2011) [11] reported that the 
HLA DRB1*03 allele is the second in frequency to 
be associated with MS, though the comparison is 
already obsolete [11]. 
Furthermore, according to Deschamps et al. (2011) 
[73], the HLA DRB1*03 is also related to neuromye-
litis optical (NMO), agreeing with the conclusions 
of previous studies in French Caucasians Zéphir et 
al., 2009) [75] and Brazilian Mulatto (Brum et al., 
2010) [76] with NMO that were positive for this 
allele [73]. On the other hand, HLA DRB1*15 seems 
to have no significant effect on the risk of NMO 
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(Deschamps et al., 2011) [73]. Moreover, there are 
consistent evidences that the HLA-DRB1*01 allele is 
strongly associated with risk of numerous autoim-
mune diseases [77, 78]. [73].
According to Kouri et al. (2011) [18], DRB1 is 
not the only susceptibility locus to MS in the MHC 
region – another examples are DQB1*0602 and 
DQA1*0102 alleles [18]. The authors reported a 
higher positivity frequency of the DQB1*0602 in 
MS patients, compared to control groups [18]. Stu-
dies with Europeans (Dunne et al., 2006) [79] and 
Caucasian (Fernández et al., 2004) [50] and certain 
non-Caucasian populations, including African Ame-
ricans (Oksenberg et al., 2004) [52] and Martinicans 
(Quelvennec et al., 2003) [80] came to the same 
conclusions. [48] 
Fernández et al. (2004) [50] reported the 
DQB1*0602 allele as the only one that kept the 
association with MS in a logistic regression model 
[18]. Fernández et al. (2009) [68] have also reported 
that the DQB1*0602 allele had a consistent positi-
vity frequency in MS patients [68]. 
Kollaee et al. (2012) [2] have also evinced that 
DQB1*0602 was slightly higher in patients with MS 
than in healthy individuals, which, however, had no 
statistical meaning [2]. Nevertheless, Dyment et al. 
(2004) [81], studying the Northern European popu-
lation, reported a high frequency of DQB1*0602 in 
MS patients, but the intense linkage disequilibrium 
of the DRB1*15-DQB1*0602 haplotype made it 
hard to define the particular susceptibility factor [2].
However, Ghabaee et al. (2009) [48] haven’t find 
any significant associations between DQB1*0602 
and MS [48]. Sardinian studies (as the one of Ma-
rrosu et al., 1993) [82] and in northeastern Italy (Zi-
vadinov et al., 2003) [83] corroborates the absence 
of that association [48].
Kouri et al (2011) [18] reported a positive asso-
ciation between the HLA DQA1*0102 allele with 
MS [18]. Marrosu et al. (2006) [84] also reported 
an elevated prevalence of DQA1*0102 allele in MS 
cases. Still, Marrosu et al (1993) [82] and Haegert 
et al (1993) [86] reported that, in Sardinians, the 
DQA1*0102 allele were less common in MS patients 
than in control groups [48]. Similar results were ob-
tained by Kalanie et al (2000) [47], with a negative 
association between HLA DQA1*0102 and MS [48]. 
The DQB1*0303 have shown to confers a pro-
tective effect against MS, being strongly negatively 
associated with the disease in Caucasian patients of 
Basque Country, in northern Spain (Fernández, et 
al. 2009). [68] But in Iranian patients, Kollaee et al. 
(2012) [2] reported no significant differences in the 
DQB1*0303 allele prevalence in MS patients and 
healthy control groups. [2].
Yoshimura et al. (2012) [1] discussed the risk con-
ferred by the DPB1*0301 allele for MS, highlighting 
that positive and negative patients for the allele had 
no significant clinical differences. [1] However, there 
have been reports of the association of this allele 
with MS in inhabitants of Hokkaido, North Japan 
[86] and in other populations, with different ethnics, 
like Australians [87] and Sardinians [88]. [1].
Fernandez et al. (2009) [68] evinced that 
DRB1*0101, DQA1*0101 and DQB1*0501 alleles 
had protective effects against MS, with significantly 
higher phenotypic frequencies in control groups 
than in sick patients [68].
Haplotypes of drb1 alleles influencing ms
There are many associations between the locus of 
the HLA-DRB1*-DQB1* alleles related in MS, already 
described in different populations. According to The 
International Multiple Sclerosis Genetics Consortium 
(2011) [39], the haplotype *15:01-*06:02 is respon-
sible for the elevated risk of MS in populations with 
northern European ancestry [89]. However, some 
populations differs on which alleles predisposes MS 
and presents different DRB1 alleles. [89].
The studies of The International Multiple Scle-
rosis Genetics Consortium (2011)39 associated the 
elevation of MS susceptibility to the presence of 
another alleles beyond DRB1*1501, as DRB1*03:01, 
DQB1*02:01 and *13:03. [89].
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The results of Celius et al. (2000) [90], the 
DRB1*1501 gen containing the HLA-DR2,DQ6 ha-
plotype, which is also associated to higher risk of 
MS, was found more often in women [46].
Kollae et al. (2012) [2], in a study with the Ira-
nian population, reported that the HLA DRB1*1501 
allele is not the only predisposing factor to MS. In 
MS patients, the odds ratio (OR = 7.792) for the 
DRB1*1501-DQB1*0602 haplotype have shown to 
be more frequent in the patients that present the 
DRB1*1501 allele alone (OR = 3.203)2. Thus, the 
haplotype must have a more significant influence 
in MS susceptibility. Moreover, those studies indica-
ted that, in genotypes containing DRB1*1501 allele 
alone, the absence of DRB1*07 allele increases the 
susceptibility of MS. [2]. The evidences were based 
in the higher prevalence of the DRB1*1501-*0701 
haplotype in MS patients, compared to control 
group in that study. [2].
Moreover, the DRB1*1501-DQB1*0602 haploty-
pe has been pointed as one the risk factors for MS 
in Northern Europe [39] and Mediterranean popu-
lations [91, 92, 89]. Analysis performed by Cocco 
et al (2012) [89] in the Sardinian population have 
confirmed that a higher MS susceptibility is asso-
ciated with the*13:03-*03:01 (OR = 2.9), *04:05-
*03:01 (OR = 2.4) and *03:01-*02:01 (OR = 2.1) 
haplotypes. Besides, the *03:01-*02:01 haplotype 
presented the and additive effect as a predisposing 
allele for MS. [89].
On the other hand, the *16:01-*05:02 haplotype, 
presenting in its recessive form in Sardinian patients 
besides the *15:02-*06:01 haplotype, are negatively 
associated to MS susceptibility. [21].
Jones et al. (2006) reported that the associations 
between the DRB1 and DQB1 alleles may influence 
the severity of the disease through unknown me-
chanisms. [93, 2].
According to Dyment et al. (2005) [12], Ramago-
palan et al. (2007) [13], Barcellos et al. (2003) [19] 
and Barcellos et al. (2006) [20], some alleles may 
influence the effect of DRB1*1501 in MS suscep-
tibility. [89] The presence of two copies of *1501 
represents a higher risk of MS; meanwhile, the as-
sociation of the *14 and *15 alleles induces a dimi-
nished risk for the disease. [89].
The conclusions of Cocco et al. (2012) [89] have 
pointed towards a protective effect of the *16:01-
*05:02 haplotype, compared to homozygotes and 
heterozygotes patients (OR = 01). However, while 
the association of the *16:01-*05:02/*16:01-*05:02 
haplotypes contributes for diminishing MS risk (OR 
= 0.2), the *16:01-*05:02 haplotype when alone 
is ineffective in providing protection in genotype 
where it is combined with other predisposing ha-
plotypes. [89] 
According to Link et al. (2012) [65], groups of 
Class I HLA alleles may interact with Class II HLA-
DRB1*15, neutralizing its negative effect as a pre-
disposing factor of MS. That mechanism may have 
altered results when different populations are con-
sidered.65
Neuromyelitis Optical (NMO) is an autoimmune 
antibody-mediated disease, commonly associated 
with other immune disturbance [94, 73]. Accor-
ding to Pittock et al (2008)94, French Caucasian 
and Brazilian mullatos probably presented a rela-
tion between DRB1*03 and NMOs. The presence 
of these alleles in the groups of patients with NMO 
in the targeted population of the study was signi-
ficantly higher. [73] Moreover, the DRB1*03 allele 
was also related to increased risk of other autoim-
mune disturbances, including MS [77, 78], which 
makes NMO an associated manifestation of MS in 
patients positive for the DRB1*03 allele. [73] Howe-
ver, the findings of Matsushita et al (2009) [95] does 
not point, in the Japanese population, towards an 
increased frequency of HLA-DRB1*0301 in patients 
with NMO and demyelinating diseases like MS. [73]
According to Alcina et al. (2012) [96], in the Class 
II HLA, the single nucleotide polymorphisms (SNPs) 
are considered the main signs to be related with 
MS. Those polymorphisms are associated with a 
higher expression of the DRB5, DRB1 and DQB1 
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genes. However, in African-Americans and Spanish 
populations, the altered expression of these genes 
is no significant. [96] The conclusions of Irizar et 
al. (2012) [46} have indicated that the DRB1, DRB5 
and DQA1 genes are expressed significantly in the 
samples positives for DRB1*1501 in their genotypes, 
with no distinctions in the expression between MS 
patients and control groups. Thereto, the expression 
of DRB5 gene have been shown to be specific of 
the DRB1*1501 allele, once the super expression of 
that gen have shown to be significantly higher in 
the individuals with positive allele. [46]
The EVI5 polymorphisms influence the disease se-
verity according to the patient’s HLA DRB1 statuses. 
For DRB1 negative patients, the disease is less seve-
re; on the other hand, in DRB1 positive patients, MS 
manifestations are severe. The patients with HLA 
DRB1 also presented worse recovery. [97-99, 100].
Zivkovic et al. (2009) [99] reported an associa-
tion between DRB1*15 and the rs3135388 poly-
morphism. The rs3135388 is useful as marker for 
the DRB1*1501 allele, helping in the detection of 
this polymorphism in clinical tests with MS patients. 
[99] According to Huang et al. (2013) [54], the ha-
plotypes formed by rs422951 and HLA-DRB1*15 
influences MS pathogenesis. [54]
CD58 and CD6 are gens related with MS. The 
most convincing relation is the one of CD58 gen, 
a CD2 binder expressed in T cells. [101, 102, 100] 
According to Kofler et al. (2011) [103], the CD6 gen 
tends to be related with a worse illness recovery, but 
it is known to be involved in the maintenance of T 
cells activation. [100] 
Conclusion
Multiple Sclerosis is an inflammatory autoimmune 
disease that affects the central nervous system and 
is determined by genetic and environmental factors. 
There is a clear association between Human Leu-
kocyte Antigen (HLA) and MS. The disease affects 
often more women, appearing earlier or later, in 
higher or lowers severity degrees. We have perfor-
med a review about MS presentation in different 
population groups.
A limitation of our study is due to the different 
outcomes the disease presents in different popula-
tions. Thus, more studies are still in need to unders-
tand better the genetic and environmental factors 
that may affect MS course. Our review highlighted 
important previous knowledge about MS and com-
piled results from many different studies, in the hope 
being useful to direct new assays on the disease.
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